Loading...
•
Jun 30, 2024
Novocure Q2 2024 Earnings Report
Reported a revenue increase driven by successful launch in France and improved U.S. approval rates.
Key Takeaways
Novocure reported a 19% year-over-year increase in net revenues, reaching $150.4 million for the second quarter of 2024. The company also presented positive results from the Phase 3 METIS trial at ASCO 2024.
Total net revenues for the quarter were $150.4 million, a 19% increase compared to the same period in 2023.
Gross margin for the quarter was 77%.
Net loss for the quarter was $33.4 million with loss per share of $0.31.
As of June 30, 2024, there were 3,963 active patients on therapy.
Revenue by Geographic Location
Forward Guidance
Novocure anticipates top-line data from phase 3 PANOVA-3 clinical trial in locally advanced pancreatic cancer in H2 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...